title: EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
authors.affiliation: Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa. Electronic address: lorenzo.fornaro@gmail.com.
authors.forename: L
authors.initials: L
authors.lastname: Fornaro
authors.affiliation: Department of Internal Medicine, Division of Pharmacology, University of Pisa, Pisa.
authors.forename: F
authors.initials: F
authors.lastname: Crea
authors.affiliation: Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa.
authors.forename: G
authors.initials: G
authors.lastname: Masi
authors.affiliation: Department of Internal Medicine, Division of Pharmacology, University of Pisa, Pisa.
authors.forename: E
authors.initials: E
authors.lastname: Paolicchi
authors.affiliation: Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa.
authors.forename: F
authors.initials: F
authors.lastname: Loupakis
authors.affiliation: Medical Oncology Unit, Department of Onco-Hematology, Azienda Ospedaliera S. Salvatore, Pesaro.
authors.forename: F
authors.initials: F
authors.lastname: Graziano
authors.affiliation: Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa.
authors.forename: L
authors.initials: L
authors.lastname: Salvatore
authors.affiliation: Division of Medical Oncology, S. Raffaele Scientific Institute, Milano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Ronzoni
authors.affiliation: Division of Medical Oncology, S. Raffaele Scientific Institute, Milano, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Ricci
authors.affiliation: Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa.
authors.forename: C
authors.initials: C
authors.lastname: Cremolini
authors.affiliation: Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa.
authors.forename: M
authors.initials: M
authors.lastname: Schirripa
authors.affiliation: Department of Internal Medicine, Division of Pharmacology, University of Pisa, Pisa.
authors.forename: R
authors.initials: R
authors.lastname: Danesi
authors.affiliation: Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa.
authors.forename: A
authors.initials: A
authors.lastname: Falcone
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D004268:DNA-Binding Proteins / Q000235:genetics*; D000071221:Enhancer of Zeste Homolog 2 Protein; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005838:Genotype; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D063151:Polycomb Repressive Complex 2; D020641:Polymorphism, Single Nucleotide / Q000502:physiology; D011379:Prognosis; D018570:Risk Assessment; D016019:Survival Analysis; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D014157:Transcription Factors; D000068258:Bevacizumab; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin